Bank of America Securities analyst Sachin Jain has reiterated their bullish stance on AZN stock, giving a Buy rating on September 30. Sachin ...

Owkin has partnered with AstraZeneca to develop an AI gBRCA pre-screen solution for breast cancer. Takeaway Points Owkin has ...

AstraZeneca AZN and partner Daiichi Sankyo announced that the FDA has accepted the supplemental biologics license application ...

AstraZeneca (NASDAQ:AZN) and partner Daiichi Sanyko (OTCPK:DSKYF)(OTCPK:DSNKY) said the FDA has accepted their application ...

Wednesday announced a clinical trial collaboration agreement with AstraZeneca (AZN) to evaluate casdatifan in combination with volrustomig for the treatment of clear cell renal cell carcinoma or ccRCC ...

The Israeli-American unicorn company ImmunAI has signed a multi-year cooperation agreement with the pharmaceutical giant ...

(Reuters) - AstraZeneca will pay $18 million to biotechnology firm Immunai Inc to use the New York-based firm's AI model of ...

Santa Barbara, Calif.– 2024 October 2 –Rupa Dainer, MD, U.S. Navy veteran and medical director, senior patient safety physician of ...

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival ...

Owkin, the first end-to-end AI-biotech that uses cutting-edge causal AI to unlock precision drug discovery, development and ...

The solution will use Owkin's data network and artificial intelligence to pre-screen for gBRCA mutations in breast cancer directly from digital pathology slides.

Dr Sanjeev Panchal, Country President and MD, AstraZeneca India, stated company's mission to bring innovative medicine faster ...